GC Biopharma

GC Biopharma Corp., established in 1967, is a prominent South Korean biopharmaceutical entity formerly known as Green Cross Corporation. Specializing in the development, manufacturing, and distribution of critical healthcare products, the company's core offerings include vaccines, plasma-derived therapies, and a range of other pharmaceutical solutions. Operating within the Pharmaceuticals and Healthcare sectors, GC Biopharma has cultivated a significant international presence, building on its foundation as a leader in the Korean pharmaceutical landscape. Its product portfolio encompasses biopharmaceuticals, vaccines, and therapeutic agents, underscoring its commitment to advancing medical science and public health.

With an employee range of 1,000-5,000 individuals, GC Biopharma maintains a substantial operational footprint. The company's headquarters are located in Yongin, South Korea, serving as a central hub for its extensive research and development initiatives and manufacturing operations. GC Biopharma is dedicated to innovation in its field, continuously working on new therapeutic candidates and improving existing treatments. To learn more about the people driving these advancements, you can Meet GC Biopharma's team and discover their expertise.

The company's ticker symbol is KRX: 006280.KS. GC Biopharma's revenue reached $1.2B, reflecting its robust market position and commercial success. Its product development spans areas such as protein-based therapies and plasma derivatives, contributing to lifesaving treatments and rehabilitation medicine. The company's strategic focus on specialty pharmaceuticals and biopharmaceutical manufacturing positions it as a key player in the global healthcare market, committed to delivering essential medical solutions.